HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genetic susceptibility to cancer from exogenous and endogenous exposures.

Abstract
The past four decades of epidemiological research have yielded valuable information on the risks of populations to environmental exposures such as tobacco, asbestos, and dietary components. Prevention efforts have been focused on large-scale population-based interventions to minimize exposure to such external carcinogens. While some cancers are beginning to show a decline from changing environmental exposures, hormone-related cancers, such as breast and prostate, are becoming more prevalent. The development of these cancers appears to be closely related to endogenous exposures to circulating steroid hormones. Although prevention trials using antihormone agents are proving successful in some instances, the long-term control of these cancers necessitates a clearer understanding of the metabolism and transport of the relevant hormone in vivo. The revolution in molecular biology has provided powerful genetic tools for evaluating mechanisms of cancer causation as well as the potential to better define individual susceptibility. Using tobacco exposure as an example, we and others have demonstrated that polymorphisms in genes controlling aromatic amine metabolism provide at least a partial explanation for ethnic and individual susceptibility to bladder cancer. Similar studies have examined genetic polymorphisms in the metabolism of tobacco smoke and lung cancer risk, red meat and colorectal cancer, and aflatoxin and liver cancer. Our current studies have pursued a similar paradigm of genetic polymorphism and individual cancer susceptibility in prostate and breast carcinogenesis. We are evaluating polymorphisms in the steroid 5 alpha-reductase type II and androgen receptor genes in relation to prostate cancer based on the evidence that intracellular dihydrotestosterone is the critical "carcinogen." We are pursuing genetic polymorphisms affecting estradiol metabolism, including those in the 17 beta-hydroxysteroid dehydrogenase 2 and estrogen receptor genes as they relate to susceptibility to breast cancer. The potential role of a polymorphism in the cytochrome P450c 17 alpha gene in both breast and prostate cancers is also being examined.
AuthorsH S Feigelson, R K Ross, M C Yu, G A Coetzee, J K Reichardt, B E Henderson
JournalJournal of cellular biochemistry. Supplement (J Cell Biochem Suppl) Vol. 25 Pg. 15-22 ( 1996) ISSN: 0733-1959 [Print] United States
PMID9027593 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Receptors, Androgen
  • Cytochrome P-450 Enzyme System
  • Oxidoreductases
  • Hydroxysteroid Dehydrogenases
  • 3(17)-hydroxysteroid dehydrogenase
  • Steroid 17-alpha-Hydroxylase
  • Cholestenone 5 alpha-Reductase
Topics
  • Adult
  • Breast Neoplasms (enzymology, genetics)
  • Carcinogenicity Tests
  • Cholestenone 5 alpha-Reductase
  • Cytochrome P-450 Enzyme System (genetics)
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Hydroxysteroid Dehydrogenases (genetics)
  • Male
  • Oxidoreductases (genetics)
  • Prostatic Neoplasms (enzymology, genetics)
  • Receptors, Androgen (genetics)
  • Steroid 17-alpha-Hydroxylase (genetics)
  • Urinary Bladder Neoplasms (enzymology, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: